Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Effect of a Photolyase-Based Medical Device on Actinic Keratosis in Phototypes III-IV Patients: Real-Life Clinical Setting.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Springer Healthcare Communications Country of Publication: Switzerland NLM ID: 101590450 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8210 (Print) NLM ISO Abbreviation: Dermatol Ther (Heidelb) Subsets: PubMed not MEDLINE
- Publication Information:
Publication: Switzerland : Springer Healthcare Communications
Original Publication: Heidelberg : Springer 2011-
- Abstract:
Competing Interests: Declarations. Conflict of Interest: Fernando Bulla has nothing to disclose. Susana Mejía has nothing to disclose. Sebastian Gil-Quiñones has nothing to disclose. Sara Cataño has nothing to disclose. Susana Sierra has nothing to disclose. Ethical Approval: The study was approved by the Institutional Review Board (IRB) on February 7, 2024. The study was conducted in accordance with the ethical standards outlined in the Declaration of Helsinki and its subsequent amendments, or with comparable ethical standards. It also adhered to the principles of Good Clinical Practices and current international and national regulations. All patients signed an informed consent authorizing their participation in the observational study and the use of their clinical data for the analysis. All patients signed an informed consent authorizing the use of their clinical data and photographic images of their faces for scientific publication.
Introduction: Actinic keratoses (AK) are premalignant skin lesions that occur in chronically photo-exposed body areas. Topical sunscreens prevent but do not reverse ultraviolet radiation (UVR)-induced damage to deoxyribonucleic acid (DNA). Eryfotona is a sunscreen product that combines high solar protection factors with light-driven DNA repair enzymes known as photolyases. This photolyase-based medical device has been shown to reduce the absolute number of AK; however, a more comprehensive assessment of AK lesions is ideal for determining its actual effect in everyday practice. The purpose of the study is to evaluate the photoprotective effect of Eryfotona sunscreen on individual AK lesions, assessing changes in their clinical and dermoscopic presentation in a real-life clinical setting and the impact on the health-related quality of life.
Methods: This was an observational, prospective, real-life study of adult patients with skin phototypes III or IV and actinic keratosis (AK) lesions on the face and scalp. Patients were treated with sunscreen containing photolyase twice daily for 6 months, with follow-up visits at 3 and 6 months. The clinical evaluation included the actinic keratosis and severity index (AKASI), the absolute number and individual dimensions of AK lesions, and the Olsen clinical classification scheme. The dermoscopic evaluation included the Zalaudek classification and assessment of lesion pigmentation. The AK Quality of Life (AKQoL) questionnaire was administered to patients during each follow-up. A repeated measures analysis of variance was performed to compare quantitative outcomes, and Fisher's exact tests were used for categorical variables.
Results: A total of 45 patients with 205 AK lesions were included; 25 patients completed both follow-ups. Clinically, there was a significant improvement from an AKASI score of 2.55 at baseline to 1.90 at 6 months (p = 0.000), and a significant difference was also observed in the dimensions of individual AK lesions and the Olsen classification between the three evaluation times (p = 0.000). Dermoscopic assessment, as classified by the Zalaudek classification, showed significant improvement throughout the three evaluations (p = 0.000). In total, 53 lesions disappeared, corresponding to 26.36% of the lesions.
Conclusions: Eryfotona provided effective and safe photoprotection and treatment of actinic keratosis on the face and scalp in patients with phototypes III and IV in the real-life clinical setting, showing promising effects on higher-grade lesions.
(© 2025. The Author(s).)
- References:
Am J Transplant. 2016 Dec;16(12):3490-3503. (PMID: 27163483)
Molecules. 2022 Sep 15;27(18):. (PMID: 36144740)
J Photochem Photobiol B. 2021 Feb;215:112113. (PMID: 33383556)
Dermatol Online J. 2017 Jan 15;23(1):. (PMID: 28329483)
J Dermatolog Treat. 2017 Aug;28(5):431-442. (PMID: 27796187)
J Am Acad Dermatol. 2018 Apr;78(4):673-681.e9. (PMID: 29217346)
J Dermatolog Treat. 2016 Nov;27(6):538-545. (PMID: 27161045)
Arch Dermatol. 2012 Oct;148(10):1159-64. (PMID: 23069952)
An Bras Dermatol. 2019 Nov - Dec;94(6):637-657. (PMID: 31789244)
Int J Dermatol. 2015;54(5):509-15. (PMID: 25865875)
Curr Probl Dermatol. 2015;46:70-6. (PMID: 25561209)
J Am Acad Dermatol. 1991 May;24(5 Pt 1):738-43. (PMID: 1869646)
Dermatol Ther (Heidelb). 2019 Mar;9(1):103-115. (PMID: 30674003)
J Eur Acad Dermatol Venereol. 2017 Sep;31(9):e401-e403. (PMID: 28294419)
J Am Acad Dermatol. 2022 Jun;86(6S):S14-S24. (PMID: 35577406)
Exp Dermatol. 2021 Sep;30(9):1324-1331. (PMID: 34081365)
Clin Dermatol. 2014 Jan-Feb;32(1):80-7. (PMID: 24314380)
Int J Cosmet Sci. 1996 Oct;18(5):203-18. (PMID: 19245449)
Photochem Photobiol. 2017 Jan;93(1):78-92. (PMID: 27991674)
Clin Cosmet Investig Dermatol. 2019 Aug 29;12:617-624. (PMID: 31695467)
J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):23-4. (PMID: 10607353)
J Eur Acad Dermatol Venereol. 2017 Jun;31(6):986-991. (PMID: 28107575)
Exp Dermatol. 2013 Jul;22(7):494-6. (PMID: 23800065)
J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1295-1302. (PMID: 28401585)
G Ital Dermatol Venereol. 2013 Dec;148(6):693-8. (PMID: 24442053)
J Dtsch Dermatol Ges. 2007 Nov;5(11):970-6. (PMID: 17908179)
Dermatol Ther (Heidelb). 2020 Oct;10(5):903-915. (PMID: 32681454)
Skin Pharmacol Physiol. 2015;28(6):281-9. (PMID: 26302873)
Dermatol Ther (Heidelb). 2019 Jun;9(2):259-270. (PMID: 30968311)
An Bras Dermatol. 2022 Mar-Apr;97(2):157-165. (PMID: 35039206)
Br J Dermatol. 2016 Dec;175(6):1391-1393. (PMID: 27167413)
J Eur Acad Dermatol Venereol. 2017 Mar;31 Suppl 2:5-7. (PMID: 28263020)
J Exp Clin Cancer Res. 2015 Aug 19;34:84. (PMID: 26282842)
- Contributed Indexing:
Keywords: Actinic; Deoxyribodipyrimidine photo-lyase; Eryfotona; Keratosis; Sunscreening agents
- Publication Date:
Date Created: 20250616 Latest Revision: 20250716
- Publication Date:
20250717
- Accession Number:
PMC12256378
- Accession Number:
10.1007/s13555-025-01455-6
- Accession Number:
40522388
No Comments.